End-of-day quote
Shanghai S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
5.74
CNY
|
+0.35%
|
|
+7.69%
|
-16.45%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
6,532
|
7,244
|
7,044
|
7,622
|
5,395
|
6,149
|
Enterprise Value (EV)
1 |
6,277
|
7,013
|
6,746
|
7,080
|
4,708
|
5,476
|
P/E ratio
|
62
x
|
93.4
x
|
82.1
x
|
81.2
x
|
43
x
|
49.9
x
|
Yield
|
0.5%
|
0.37%
|
0.37%
|
0.39%
|
0.77%
|
0.95%
|
Capitalization / Revenue
|
5.95
x
|
6.52
x
|
7.55
x
|
5.04
x
|
3.75
x
|
5.2
x
|
EV / Revenue
|
5.71
x
|
6.31
x
|
7.23
x
|
4.69
x
|
3.27
x
|
4.63
x
|
EV / EBITDA
|
107
x
|
-193
x
|
-128
x
|
-107
x
|
137
x
|
76.5
x
|
EV / FCF
|
-61.5
x
|
-40.4
x
|
-348
x
|
-72.6
x
|
-474
x
|
-78.6
x
|
FCF Yield
|
-1.63%
|
-2.48%
|
-0.29%
|
-1.38%
|
-0.21%
|
-1.27%
|
Price to Book
|
2.45
x
|
2.52
x
|
2.34
x
|
2.6
x
|
1.84
x
|
2.09
x
|
Nbr of stocks (in thousands)
|
1,207,057
|
1,207,057
|
1,207,057
|
1,207,057
|
1,207,057
|
1,207,057
|
Reference price
2 |
6.940
|
8.040
|
8.120
|
8.880
|
5.850
|
6.870
|
Announcement Date
|
4/15/19
|
4/27/20
|
4/20/21
|
4/18/22
|
4/27/23
|
4/19/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,099
|
1,112
|
932.7
|
1,511
|
1,440
|
1,183
|
EBITDA
1 |
58.54
|
-36.26
|
-52.9
|
-66.18
|
34.33
|
71.58
|
EBIT
1 |
31.09
|
-62.83
|
-79.45
|
-89.64
|
11.05
|
48.68
|
Operating Margin
|
2.83%
|
-5.65%
|
-8.52%
|
-5.93%
|
0.77%
|
4.12%
|
Earnings before Tax (EBT)
1 |
180.1
|
132.4
|
105.4
|
103.7
|
230.3
|
207.2
|
Net income
1 |
135.3
|
103.9
|
119.4
|
132.1
|
164.1
|
166
|
Net margin
|
12.31%
|
9.35%
|
12.8%
|
8.74%
|
11.39%
|
14.04%
|
EPS
2 |
0.1120
|
0.0861
|
0.0989
|
0.1094
|
0.1359
|
0.1376
|
Free Cash Flow
1 |
-102.1
|
-173.6
|
-19.38
|
-97.51
|
-9.928
|
-69.65
|
FCF margin
|
-9.3%
|
-15.62%
|
-2.08%
|
-6.45%
|
-0.69%
|
-5.89%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.0350
|
0.0300
|
0.0300
|
0.0350
|
0.0450
|
0.0650
|
Announcement Date
|
4/15/19
|
4/27/20
|
4/20/21
|
4/18/22
|
4/27/23
|
4/19/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
255
|
232
|
299
|
541
|
687
|
672
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-102
|
-174
|
-19.4
|
-97.5
|
-9.93
|
-69.7
|
ROE (net income / shareholders' equity)
|
4.12%
|
2.8%
|
2.33%
|
2.16%
|
4.78%
|
4.71%
|
ROA (Net income/ Total Assets)
|
0.41%
|
-0.81%
|
-0.92%
|
-1.02%
|
0.13%
|
0.62%
|
Assets
1 |
32,717
|
-12,796
|
-12,963
|
-12,910
|
121,884
|
26,848
|
Book Value Per Share
2 |
2.830
|
3.190
|
3.470
|
3.420
|
3.180
|
3.280
|
Cash Flow per Share
2 |
0.2800
|
0.3200
|
0.3300
|
0.2700
|
0.3500
|
0.4200
|
Capex
1 |
106
|
239
|
155
|
74
|
15.9
|
61.8
|
Capex / Sales
|
9.66%
|
21.46%
|
16.6%
|
4.9%
|
1.11%
|
5.22%
|
Announcement Date
|
4/15/19
|
4/27/20
|
4/20/21
|
4/18/22
|
4/27/23
|
4/19/24
|
|
1st Jan change
|
Capi.
|
---|
| -16.45% | 717M | | +19.27% | 43.75B | | +25.15% | 22.06B | | +15.11% | 14.46B | | +12.33% | 13.62B | | +38.36% | 11.61B | | -8.41% | 6.9B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +10.21% | 5.32B |
Generic Pharmaceuticals
|